Keyphrases
Adverse Drug Events
15%
Alpha Inhibitors
7%
Anemia
7%
Belzutifan
100%
Center Prior
7%
Clear Cell Renal Cell Carcinoma (ccRCC)
7%
Clinical Activity
7%
Clinical Outcomes
7%
Confidence Interval
15%
Corpus Callosum Agenesis
100%
Distinct Patterns
33%
Dose Reduction
7%
Female Fetus
100%
Follow-up Time
7%
Golf Club
10%
Heavily Pretreated
7%
Horn Morphology
20%
Hypoxia
7%
Hypoxia-inducible factor-2α (HIF-2α)
7%
Immune Checkpoint Therapy
15%
Intellectual Disability
33%
Intermediate Risk
7%
MD Anderson Cancer Center
15%
Median Overall Survival
7%
Median Progression-free Survival
7%
Metastasizing
7%
Metastatic RCC
7%
Metastatic Renal Cell Carcinoma (mRCC)
100%
Metastatic Site
7%
New Medicines
7%
Objective Response Rate
15%
Overall Survival
7%
Partial Agenesis
40%
Pattern of Malformation
33%
Paucity
7%
Progression-free Survival
15%
Radiologists
7%
Real-world Experience
7%
Response Evaluation Criteria in Solid Tumors (RECIST)
7%
Risk Disease
7%
Subsequent Pregnancy
33%
Survival Response
7%
Tolerability
100%
Treatment Line
7%
Treatment-related Mortality
7%
USP9X
100%
Vascular Endothelial Growth Factor Receptor Inhibitor
15%
Von Hippel-Lindau Disease
7%
Whole Exome Sequencing
100%
X-linked Genes
33%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Drug Reaction
40%
Anemia
20%
Diseases
20%
Hypoxia
20%
Hypoxia Inducible Factor
20%
Kidney Cancer
20%
Malignant Neoplasm
80%
Overall Survival
40%
Progression Free Survival
60%
Protein Tyrosine Kinase
40%
Protein Tyrosine Kinase Inhibitor
40%
Prothrombin
20%
Renal Cell Carcinoma
100%
Retrospective Study
20%
Solid Malignant Neoplasm
20%
Tolerability
100%
Vasculotropin Receptor
40%
Von Hippel Lindau Disease
20%